DVX 201
Alternative Names: DVX-201Latest Information Update: 08 Jan 2024
At a glance
- Originator Deverra Therapeutics
- Developer Deverra Therapeutics; Duke University
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia; COVID-19 pneumonia; Myelodysplastic syndromes
Most Recent Events
- 08 Jan 2024 Coeptis plans a Phase II trial in Respiratory tract infections
- 14 Sep 2023 Pooled adverse events data from two phase I trials in Acute myeloid leukaemia and Myelodysplastic syndromes and COVID-19 pneumonia released by Coeptis Therapeutics
- 17 Aug 2023 Coeptis Therapeutics completes licensing of DVX 201 from Deverra Therapeutics